- Home
- AFRI vs FENC Comparison
AFRI vs FENC Comparison
Compare AFRI & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$9.53
HOLD
Current Price
$6.30
Company Overview
Basic Information| Metric | AFRI | FENC |
|---|---|---|
| Founded | 1943 | 1996 |
| Country | Gibraltar | United States |
| Employees | 600 | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.0M | 266.4M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | AFRI | FENC |
|---|---|---|
| Price | $9.53 | $6.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 6.6K | ★ 191.9K |
| Earning Date | 04-29-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $75.81 |
| Revenue Next Year | N/A | $25.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.47 | $4.68 |
| 52 Week High | $11.42 | $9.92 |
Technical Indicators
Market Signals| Indicator | AFRI | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 37.39 |
| Support Level | $9.40 | N/A |
| Resistance Level | $10.00 | $9.09 |
| Average True Range (ATR) | 0.30 | 0.47 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 77.05 | 23.58 |
Price Performance
Historical Comparison AFRI
FENC
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.